Home Sleep Apnea Testing Market to Reach USD 996.6 Million by 2036, Driven by Expanding Telehealth Adoption and Rising Demand for Portable Sleep Diagnostics

Future Market Insights projects the global home sleep apnea testing market will rise from $734.4M in 2026 to $996.6M by 2036, a 3.1% CAGR, supported by growing telehealth/remote monitoring adoption and wearable + AI-enabled analytics. The article highlights product momentum from FDA-cleared solutions (e.g., ResMed’s NightOwl) and regulatory clearance for wearable diagnostic tech (e.g., Huxley Medical’s SANSA patch). Key constraints include lower data capture at home versus in-lab polysomnography and reimbursement variability, but overall demand growth is positioned as steady through 2036.

Analysis

This is a workflow shift, not a demand shock. The economic value should accrue less to the testing kit itself and more to whoever controls the diagnosis-to-treatment funnel, clinician software, and repeat consumables; that makes RMD the cleanest public beneficiary, while small sleep-lab operators and fixed-cost diagnostic centers face utilization pressure as volume migrates away from overnight facilities. The second-order loser is any vendor selling a standalone device without a software or channel moat: as procurement moves into bundled telehealth workflows, hardware gets more price-competitive and margin capture moves upstream into data review and downstream into therapy.

The important distinction is horizon. Near term, this is mostly a sentiment read-through with little standalone catalyst unless reimbursement expands or a major payer changes eligibility rules; over 1-3 months the market may barely care. Over 6-18 months, the thesis becomes more meaningful if remote-prescribing and cloud review continue to reduce friction, because that improves diagnosis conversion and ultimately feeds PAP and mask replacement demand. What breaks the story is payer tightening, more insistence on in-lab confirmation for complex patients, or regulatory/cybersecurity friction that raises the cost of connected workflows.

Contrarian take: the consensus is likely overstating the size of the prize. A 3.1% CAGR points to steady share migration, not a breakout category, and much of the growth is re-routing existing diagnostic spend from labor-intensive labs into cheaper home workflows rather than expanding the total profit pool. That argues for selective exposure to incumbents with ecosystem leverage, not a broad bullish basket on home-testing hardware. The highest-quality moat is in integrated respiratory platforms, not in the test itself.

Key Decisions for Investors

• Accumulate RMD on healthcare pullbacks over the next 1-3 months; best way to express the theme because incremental screening should lift downstream PAP/mask conversion more than it lifts the testing market itself. Risk/reward is favorable on a 6-18 month view, but trim if payer commentary shows home-test eligibility is narrowing.
• Do not chase a broad basket of standalone home sleep-testing names; treat this as a margin-compression theme for pure-play device vendors unless they also own software, payer contracts, or a therapy platform. This is more likely to be a winner-take-most market than a rising tide for every participant.
• Set a policy alert on CMS and top commercial payers: if reimbursement broadens for home testing, add to RMD and connected-care beneficiaries; if reimbursement becomes more restrictive, fade the trade. That policy gate is the key falsifier over the next 1-2 quarters.
• For a tactical relative-value expression, consider long RMD / short IHI for 3-6 months to isolate decentralized-care alpha from broad medtech beta. Expect modest outperformance rather than a home-run; cover if healthcare leadership rotates away from respiratory exposure.
• If you want optionality instead of outright equity risk, use a medium-dated RMD call spread into the next two earnings cycles only if data show continued prescription-to-testing conversion. Without that confirmation, the theme is too slow-moving for aggressive options positioning.